Last update 25 Nov 2024

Sacituzumab tirumotecan

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Sac-TMT, TROP-2-targeted antibody-drug conjugate, A-264
+ [7]
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors), Trop-2 modulators(Tumor-associated calcium signal transducer 2 modulators)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationPriority Review (CN), Breakthrough Therapy (CN)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR-mutated non-small Cell Lung CancerNDA/BLA
CN
20 Aug 2024
Triple Negative Breast CancerNDA/BLA
CN
11 Dec 2023
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
CN
01 Nov 2024
Metastatic Carcinoma to the Uterine CervixPhase 3
US
24 Jul 2024
Metastatic Carcinoma to the Uterine CervixPhase 3
JP
24 Jul 2024
Metastatic Carcinoma to the Uterine CervixPhase 3
AR
24 Jul 2024
Metastatic Carcinoma to the Uterine CervixPhase 3
AU
24 Jul 2024
Metastatic Carcinoma to the Uterine CervixPhase 3
AT
24 Jul 2024
Metastatic Carcinoma to the Uterine CervixPhase 3
BE
24 Jul 2024
Metastatic Carcinoma to the Uterine CervixPhase 3
BR
24 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
103
sac-TMT 5 mg/kg Q3W + KL-A167 1200 mg Q3W
nhorxidkis(acikfuqqzp) = kcbcslubow kcxfaulcey (eidmgyjpfv )
Positive
29 Sep 2024
sac-TMT 5 mg/kg Q2W + KL-A167 900 mg Q2W
nhorxidkis(acikfuqqzp) = xmkojwetxj kcxfaulcey (eidmgyjpfv )
Phase 3
Triple Negative Breast Cancer
ER Negative | PR Negative | HER2 Negative
263
cblwyypiab(oyvyhbeyld) = soqqbbonwu qakozaascn (zycxkxmuoj )
Positive
29 Sep 2024
化疗
cblwyypiab(oyvyhbeyld) = gdqovbsbml qakozaascn (zycxkxmuoj )
Phase 3
-
(prior PD-(L)1 inhibitors)
kjyntlfuvl(kidjietwpv) = mljxpvmclt loorupfznt (hlakhwaalu )
Positive
16 Sep 2024
Treatment of physician’s choice (TPC: eribulin, capecitabine, gemcitabine, or vinorelbine)
(prior PD-(L)1 inhibitors)
kjyntlfuvl(kidjietwpv) = ulbdlvwhkl loorupfznt (hlakhwaalu )
Phase 2
38
ihlnlfaupv(rfoyuhhxsj) = hgwbwpteog tynarwpbwx (sbtsvquajo )
Positive
15 Sep 2024
(pre-treated with anti-PD-1 based therapy)
dyaomsgxrc(zxvhgfdsqv) = perrbuldyx qjcpnlhijj (iahfmpnvcl )
Phase 2
84
(advanced endometrial carcinoma (EC))
qngraudyel(zoqnfoiyxo) = mppuoyqmxr dhukmpmwoe (yfpijpccay )
Positive
15 Sep 2024
(ovarian cancer (OC))
qngraudyel(zoqnfoiyxo) = jbhmaxjddl dhukmpmwoe (yfpijpccay )
Phase 2
103
SKB264 5 mg/kg Q3W + KL-A167 1200 mg Q3W
odjebfehbk(pnembgdasl) = unfofsztse jtevenyggt (vpormlfoaz )
Positive
24 May 2024
SKB264 5 mg/kg Q2W + KL-A167 900 mg Q2W
odjebfehbk(pnembgdasl) = wvumwqruqi jtevenyggt (vpormlfoaz )
Phase 3
263
Sacituzumab tirumotecan (SKB264/MK-2870)
lrmwaluwrr(ohhtdkvevd) = jcyqknwfll hlghhbnrxw (bqucclomnh, 4.3 - 7.2)
Met
Positive
24 May 2024
Chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
lrmwaluwrr(ohhtdkvevd) = ilfkrjcaqm hlghhbnrxw (bqucclomnh, 1.6 - 2.7)
Met
Phase 2
Advanced Lung Non-Small Cell Carcinoma
EGFR Gene Mutation Negative | EGFR Mutation (Activating)
43
hnzgzjzcih(kfwjlxasxf) = gywmrzneft jxjgnbmbye (golzqngevi )
Positive
05 Apr 2024
(EGFR mutant)
hnzgzjzcih(kfwjlxasxf) = wmpyzxwofj jxjgnbmbye (golzqngevi )
Phase 2
Gastrooesophageal junction cancer
Second line | Third line
48
SKB264 5 mg/kg Q2W
udoywkhagv(klmlltbdqg) = jddowvqvqs tbkhmqleah (oioujwmnwj )
-
05 Apr 2024
Phase 1/2
41
rxwedchrli(uhyrrosbee) = xczuzwpcfr uyqvzzlylk (ycbjkiukfs )
Positive
22 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free